CUNY-affiliated neurotechnology company wins Innovation Prize 2016

October 18, 2016

PathMaker Neurosystems ("PathMaker"), a clinical-stage neurotechnology company developing non-invasive neurotherapy systems to treat neuromotor disorders, has been named as the Recipient of the Universal Biotech Innovation Prize 2016 in the global competition that offers "a glimpse of the future of life sciences." The Innovation Prize awards were announced following presentations during Innovation Days, an international event gathering leading companies and researchers in the Life Sciences field, held October 3-4, 2016, at the Maison de la Chimie in Paris, France.

The international competition, started in 2009 by Universal Biotech and now in its eighth year, honors the world's most innovative startups and the best academic research groups that are "developing cutting-edge technologies in the field of life sciences." Of the 259 entrants from 38 countries this year, PathMaker was selected after four evaluation rounds as Innovation Prize 2016 Laureate, with awards given out in both the MedTech and Biotech categories. Companies were analyzed according to the scientific quality of the innovation, intellectual property, quality of their human resources, project feasibility, and market access strategy. The entrants included applications from the Biotech, Medtech, e-health and diagnostics segments of the life sciences field. The jury included leading and prominent experts from major healthcare companies, pharmaceutical companies, biotechnology societies, and legal firms with extensive experience reviewing novel technologies.

"At PathMaker, we are tremendously honored and excited to have been awarded the Innovation Prize 2016," said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. "This prestigious prize reflects not only the rapid progress our expert team has made in translating fundamental discoveries into novel therapeutic devices but the human impact our non-invasive technology will have for patients with paralysis, muscle weakness and spasticity. As the leading company developing non-invasive neuromodulation products for the treatment of neuromotor conditions, we are seeing major interest in our technology from leading clinical institutions and other groups."

To treat these conditions, PathMaker has exclusively licensed intellectual property from the City University of New York developed by neuroscientist Zaghloul Ahmed, PhD, Professor and Chairman, Department of Physical Therapy, College of Staten Island and Professor of Neuroscience, Center for Developmental Neuroscience and CUNY Graduate Center. As PathMaker's scientific founder, Dr. Ahmed commented, "We are very pleased to see the international recognition that our groundbreaking technology and world-class team at PathMaker is getting. We are working to bring the novel treatments enabled by our technology to patients as rapidly as possible."

PathMaker is developing breakthrough non-invasive systems that treat patients suffering from neural pathway disruptions such as stroke, cerebral palsy, multiple sclerosis, Parkinson's disease, traumatic brain injury and spinal cord injury. PathMaker's first product, MyoRegulator™, provides an innovative treatment for muscle spasticity and is now in IRB-approved human clinical trials. This intervention suppresses the hyper-excitable spinal circuits that characterize spasticity, normalizing function in previously untreatable muscles. The company's second product, MyoAmplifier™, provides an advanced non-invasive platform that treats paralysis and muscle weakness.
-end-
About PathMaker Neurosystems Inc.

PathMaker Neurosystems Inc. is a clinical-stage neurotechnology company developing non-invasive neurotherapy systems based on Coordinated Multi-site Neurostimulation. With offices in Boston (US) and Paris (France), PathMaker is moving forward a trans-Atlantic strategy to rapidly bring to market entirely novel, breakthrough approaches to non-invasively treating neuromotor disorders. More than 48 million patients in the US, Europe, and China suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson's disease and other neurological disorders. At PathMaker, we are opening up a new era of non-invasive neurotherapy for patients suffering from chronic neuromotor conditions. Visit the company website at http://www.pmneuro.com.

About CUNY

The City University of New York is the nation's leading urban public university. Founded in New York City in 1847, the University comprises 24 institutions: 11 senior colleges, seven community colleges, and additional professional schools. The University serves nearly 275,000 degree-credit students and 218,083 adults, continuing, and professional education students.

For more information, please contact Shante Booker (shante.booker@cuny.edu) or visit http://www.cuny.edu/research

The City University of New York

Related Physical Therapy Articles from Brightsurf:

NIH gene therapy startup to increase AAV gene therapy efficiency
Maximizing the efficiency of the adeno-associated virus (AAV) platform for gene therapy is the aim of a new pilot project of the National Institutes of Health (NIH).

Factors maximize impact of yoga, physical therapy on back pain in underserved population
New research shows that people with chronic low back pain (cLBP) have better results from yoga and physical therapy compared to reading evidence-based self-help materials.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

New hope for ACL injuries: Adding eccentric exercises could improve physical therapy outcomes
People with anterior cruciate ligament injuries can lose up to 40% of the muscle strength in the affected leg--with muscle atrophy remaining a big problem even after ACL reconstruction and physical therapy.

Dual therapy reduces risk for bleeding better than triple therapy for patients with atrial fibrillation
Use of dual therapy with a direct oral anticoagulant (DOAC) plus P2Y12 inhibitor was associated with reduced risk for major bleeding compared with triple therapy with a vitamin K antagonist (VKA) plus aspirin and P2Y12 inhibitor for patients with nonvalvular atrial fibrillation after percutaneous coronary intervention (PCI).

Light therapy for immune cells helps with side effects of cancer therapy
A frequent side effect of cancer immunotherapies can probably be stopped by light activation of immune cells, as researchers at the Medical Center -- University of Freiburg have shown.

Virtual physical therapy after knee replacement brings similar outcomes, lower costs
A virtual system for in-home physical therapy (PT) provides good outcomes for patients undergoing rehabilitation following total knee arthroplasty (TKA) -- with lower costs than traditional in-person PT, reports a study in the Jan.

Individualized physical therapy reduces incontinence, pain in men after prostate surgery
For decades, therapy to strengthen pelvic muscles has been the standard treatment for men dealing with urinary incontinence after prostate surgery.

Yoga and physical therapy as treatment for chronic lower back pain also improves sleep
Yoga and physical therapy (PT) are effective approaches to treating co-occurring sleep disturbance and back pain while reducing the need for medication, according to a new study from Boston Medical Center.

BU finds physical therapy access may reduce opioid prescriptions
Low back pain is one of the most common conditions Americans seek care for--and one of the more common reasons for an opioid prescription.

Read More: Physical Therapy News and Physical Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.